Engineering antibody fragments to fold in the absence of disulfide bonds

Protein Science

Volumn 18, Issue 2, 2009, Pages 259-267

  Seo, Min Jeong ^a,b   Jeong, Ki Jun ^c   Leysath, Clinton E ^b   Ellington, Andrew D ^b   Iverson, Brent L ^b   Georgiou, George ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Directed evolution; Disulfide bonds; Intrabodies; Protein structure folding

Indexed keywords

ANTIBODY; DSBA PROTEIN; MUTANT PROTEIN;

ARTICLE; DISULFIDE BOND; ENZYME INACTIVATION; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN ISOLATION;

AMINO ACID SEQUENCE; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CYSTEINE; DIRECTED MOLECULAR EVOLUTION; DISULFIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLOW CYTOMETRY; GENE LIBRARY; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; MUTATION; OXIDATION-REDUCTION; PROTEIN CONFORMATION; PROTEIN DISULFIDE-ISOMERASES; PROTEIN ENGINEERING; PROTEIN FOLDING; SEQUENCE ALIGNMENT; SERINE;

EID: 59949099244     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.31     Document Type: Article

References (42)

1. Proba K, Worn A, Honegger A, Pluckthun A (1998) Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 275:245-253.
2. Worn A, Pluckthun A (1998) Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 37: 13120-13127.
3. Hagihara Y, Mine S, Uegaki K (2007) Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J Biol Chem 282:36489-36495.
4. Cattaneo A, Biocca S (1999) The selection of intracellular antibodies. Trends Biotechnol 17:115-121.
5. Lo AS, Zhu Q, Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 181:343-373.
6. Messer A, McLear J (2006) The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases. Bio Drugs 20:327-333.
7. Williams BR, Zhu Z (2006) Intrabody-based approaches to cancer therapy: status and prospects. Curr Med Chem 13:1473-1480.
8. Cardinale A, Biocca S (2008) Combating protein misfold- ing and aggregation by intracellular antibodies. Curr Mol Med 8:2-11.
9. Proba K, Honegger A, Pluckthun A (1997) A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol 265:161-172.
10. Tavladoraki P, Girotti A, Donini M, Arias FJ, Mancini C, Morea V, Chiaraluce R, Consalvi V, Benvenuto E (1999) A single-chain antibody fragment is functionally expressed in the cytoplasm of both Escherichia coli and transgenic plants. Eur J Biochem 262:617-624.
11. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A (1999) Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci USA 96:11723-11728.
12. Jermutus L, Honegger A, Schwesinger F, Hanes J, Pluckthun A (2001) Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci USA 98:75-80.
13. der Maur AA, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C, Escher D, Pluckthun A, Barberis A (2002) Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem 277:45075-45085.
14. Vascotto F, Visintin M, Cattaneo A, Burrone OR (2005) Design and selection of an intrabody library produced denovo for the non-structural protein NSP5 of rotavirus. J Immunol Methods 301:31-40.
15. Koch H, Grafe N, Schiess R, Pluckthun A (2006) Direct selection of antibodies from complex libraries with the protein fragment complementation assay. J Mol Biol 357: 427-441.
16. Visintin M, Melchionna T, Cannistraci I, Cattaneo A (2008) In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets. J Biotechnol 135:1-15.
17. Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, Marasco WA (2004) Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol 335:193-207.
18. Desiderio A, Franconi R, Lopez M, Villani ME, Viti F, Chiaraluce R, Consalvi V, Neri D, Benvenuto E (2001) A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold. J Mol Biol 310:603-615.
19. Donini M, Morea V, Desiderio A, Pashkoulov D, Villani ME, Tramontano A, Benvenuto E (2003) Engineering stable cytoplasmic intrabodies with designed specificity. J Mol Biol 330:323-332.
20. Philibert P, Stoessel A, Wang W, Sibler AP, Bec N, Larroque C, Saven JG, Courtete J, Weiss E, Martineau P (2007) A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol 7:81.
21. Shaki-Loewenstein S, Zfania R, Hyland S, Wels WS, Benhar I (2005) A universal strategy for stable intracellular antibodies. J Immunol Methods 303:19-39.
22. Ritz D, Beckwith J (2001) Roles of thiol-redox pathways in bacteria. Annu Rev Microbiol 55:21-48.
23. Nakamoto H, Bardwell JC (2004) Catalysis of disulfide bond formation and isomerization in the Escherichia coli periplasm. Biochim Biophys Acta 1694:111-119.
24. Leichert LI, Jakob U (2004) Protein thiol modifications visualized in vivo. PLoS Biol 2:e333.
25. Masip L, Klein-Marcuschamer D, Quan S, Bardwell JC, Georgiou G (2008) Laboratory evolution of Escherichia coli thioredoxin for enhanced catalysis of protein oxidation in the periplasm reveals a phylogenetically conserved substrate specificity determinant. J Biol Chem 283:840-848.
26. Harvey BR (2003) Anchored Periplasmic Expression (APEx): a versatile technology for the flow cytometric selection of high affinity antibodies from Eshcerichia coli expressed libraries. Ph.D. Thesis. Austin: The University of Texas, pp 10-14.
27. Ki JJ, Kawarasaki Y, Gam J, Harvey BR, Iverson BL, Georgiou G (2004) A periplasmic fluorescent reporter protein and its application in high-throughput membrane protein topology analysis. J Mol Biol 341:901-909.
28. Jeong KJ, Seo MJ, Iverson BL, Georgiou G (2007) APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering. Proc Natl Acad Sci USA 104:8247-8252.
29. Mazor Y, Van Blarcom T, Mabry R, Iverson BL, Georgiou G (2007) Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 25:563-565.
30. Little SF, Leppla SH, Cora E (1988) Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56:1807-1813.
31. Krishnanchettiar S, Sen J, Caffrey M (2003) Expression and purification of the Bacillus anthracis protective antigen domain 4. Protein Expr Purif 27:325-330.
32. Joly JC, Swartz JR (1997) In vitro and in vivo redox states of the Escherichia coli periplasmic oxidoreductases DsbA and DsbC. Biochemistry 36:10067-10072.
33. Drummond DA, Iverson BL, Georgiou G, Arnold FH (2005) Why high-error-rate random mutagenesis libraries are enriched in functional and improved proteins. J Mol Biol 350:806-816.
34. Ladbury JE, Wynn R, Thomson JA, Sturtevant JM (1995) Substitution of charged residues into the hydrophobic core of Escherichia coli thioredoxin results in a change in heat capacity of the native protein. Biochemistry 34: 2148-2152.
35. Tanaka T, Rabbitts TH (2008) Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds. J Mol Biol 376:749-757.
36. Ribnicky B, Van Blarcom T, Georgiou G. (2007) A scFv antibody mutant isolated in a genetic screen for improved export via the twin arginine transporter pathway exhibits faster folding. J Mol Biol 369:631-639.
37. Harvey BR, Georgiou G, Hayhurst A, Jeong KJ, Iverson BL, Rogers GK (2004) Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 101:9193-9198.
38. Jung ST, Jeong KJ, Iverson BL, Georgiou G (2007) Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. Biotechnol Bioeng 98:39-47.
39. Griswold KE, Kawarasaki Y, Ghoneim N, Benkovic SJ, Iverson BL, Georgiou G (2005) Evolution of highly active enzymes by homology-independent recombination. Proc Natl Acad Sci USA 102:10082-10087.
40. Calhoun DB, Englander SW (1985) Internal protein motions, concentrated glycerol, and hydrogen exchange studied in myoglobin. Biochemistry 24:2095-2100.
41. Segatori L, Paukstelis PJ, Gilbert HF, Georgiou G (2004) Engineered DsbC chimeras catalyze both protein oxidation and disulfide-bond isomerization in Escherichia coli: reconciling two competing pathways. Proc Natl Acad Sci USA 101:10018-10023.
42. Hayhurst A, Happe S, Mabry R, Koch Z, Iverson BL, Georgiou G (2003) Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J Immunol Methods 276:185-196.